Latest Product Development News

Acrux has amended its licensing agreement with Gedeon Richter to bring its Estradiol spray Lenzetto® to Australia, unlocking up to AUD 5.4 million in milestone payments and addressing a critical shortage in Menopause Hormone Therapy products.

Knosys has locked in a two-year, $3.8 million contract extension with ANZ, with full payment received upfront. This deal underpins Knosys’s role in ANZ’s AI integration efforts and strengthens the company’s cash position.

HighCom Limited has locked in a $4.5 million loan facility with Commonwealth Bank, replacing its US debt and complementing a recent $7.8 million capital raise to fuel working capital and sales expansion.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

Ainsworth Game Technology posted a 10% revenue increase in FY25 to $291 million, driven by strong Asia Pacific growth, while North American challenges weigh on H1 2026 outlook.

PaySauce has successfully launched its Global Payroll Platform in Australia, targeting nearly 700,000 micro-businesses, supported by a $5 million capital raise and steady growth in its New Zealand operations.

5E Advanced Materials has requested suspension of its shares from ASX trading to enable its removal from the official list, marking a significant shift in its market presence.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.

ASX Limited projects a significant 18-21% rise in expenses for FY27 driven by technology modernisation and regulatory response, while increasing capital expenditure guidance to up to $200 million.

Fisher & Paykel Healthcare posted a 14% revenue increase to NZ$2.31 billion and a 24% rise in net profit to NZ$468.5 million for FY2026, driven by strong hospital product sales and ongoing innovation.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.